[Edaily Reporter Kwon Oh Seok ] C&R Research(359090), a leading domestic contract research organization (CRO), is showing a sharp improvement in its financial performance, driven by a surge in overseas orders. (Photo courtesy of C&R Research) According to a report by the independent research firm Value Finder on the 16th, C&R Research’s third-quarter consolidated operating profit reached 2.2 billion won (operating profit margin of 11.4%), marking its highest profitability of the year and successfully returning to profitability on a cumulative basis. Consolidated revenue for the same period totaled 19.3 billion won, a 22.2% increase year-over-year. In particular, the recovery in profitability of its core business is notable. On a non-consolidated basis, third-quarter revenue was 17 billion won (up 14.9% year-over-year), and operating profit was 3.1 billion won (up 166%), with the operating profit margin soaring to the 18% range. Given the nature of the CRO industry, where fixed costs such as labor expenses account for a high proportion of total expenses, this result reflects the company’s entry into the so-called “profit leverage” phase—where additional revenue directly translates into profit once a certain revenue threshold is exceeded. Overseas markets are the key driver of this revenue growth. Cumulative new orders for the first three quarters totaled 75 billion won (53.9 billion won domestically and 21.1 billion won overseas), already exceeding last year’s annual order volume (53.2 billion won) by 41%. Of this total, global order volume has grown to 2.3 times last year’s annual figure (9.5 billion won). As the company is pursuing additional multi-country clinical trial contracts in the fourth quarter, the upward trend in its annual order backlog is expected to become even steeper. The company’s external standing and the success of its new business ventures are also contributing to this growth. Last month, C&R Research ranked 47th (15th in Asia-Pacific) in the “CareerAidHub” global CRO rankings, placing it on par with global publicly traded companies beyond the domestic market. Trial Informatics, a subsidiary leading the transition to a data-driven CRO, also saw its third-quarter revenue surge 171% year-over-year to 2.4 billion won, significantly narrowing its operating loss to 100 million won (compared to an 800 million won loss in the same period last year). The company is also expanding its real-world data (RWD) business by recently securing a U.S. medical data supply chain. The market views the turnaround in its core business, coupled with solid asset value, as the key to a stock price revaluation. The appraised value of its owned office buildings alone is estimated at over 40 billion won—exceeding its current market capitalization—which is seen as providing a floor against further price declines. Jeon Woo-bin, an analyst at Value Finder, stated, “Driven by an expansion in the order backlog, this year’s annual revenue is expected to exceed last year’s level,” adding, “As a company-wide earnings turnaround becomes visible, a phased revaluation of the company’s value is expected as profit leverage is confirmed.”
“(For semiconductor equipment manufacturers), the development environment and the actual mass production line environment are so different that even if a product passes in-house testing, it sometimes …
Thinkware Systems Corporation(084730)announced on the 16th that its consolidated revenue for the third quarter of this year reached 358.3 billion won. The company’s strategy is to secure new growth en…
Naver (NAVER(035420)) is expanding its Smart Store-centered business-to-consumer (B2C) ecosystem into the business-to-business (B2B) sector. The company is connecting businesses with high demand for b…